Roche and Mylan settle a scrap over Herceptin, clearing path to a global launch of a knockoff drug
Two weeks ago Roche shares jumped on the news that the pharma giant had scored winning Phase III data supporting the combination of Herceptin …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
